文献速递血脂与心血管预防

技术辅助自我筛选非处方他汀治疗候选者的研究

Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究纳入500名参与者(其中83人读写能力有限),通过家用网络应用程序自我评估是否适合使用5mg瑞舒伐他汀,并与临床医生盲法独立评估的结果进行对比。主要终点为参与者自我选择与医生评估的一致性,结果显示481名(96.2%,95%CI 94.1%-97.7%)参与者的一致性好,其中23人(4.6%)被认为适合治疗,458人(91.6%)被认为不适合。结论认为技术辅助的消费者自我筛选与医生选择具有高度一致性。

要点

  • 技术辅助自我筛选与医生评估的一致率达96.2%。
  • 不一致主要源于错误拒绝(14例)而非错误接受(3例)。
  • 读写能力有限者也可完成网络自我评估。

核心结论

  • 技术辅助的消费者自我筛选用于他汀治疗与临床医生评估显示出高度一致性。

研究设计与样本

  • 共500名参与者,其中83人读写能力有限,完成家用网络应用程序评估5mg瑞舒伐他汀的适用性,随后由盲法临床医生独立进行网络评估。

主要发现

  • 主要终点一致率为96.2%(481/500,95%CI 94.1%-97.7%)。
  • 一致者中23人(4.6%)被判定适合治疗,458人(91.6%)被判定不适合。
  • 不一致包括3例错误自我选择「OK to use」、14例错误拒绝「not right for you」和2例错误「ask a doctor」。

临床怎么用

  • 该技术辅助自我筛选方法或可安全扩大他汀的可及性,但需注意错误拒绝多于错误接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although statins reduce cardiovascular morbidity and mortality, only about one-half of eligible patients receive treatment. Safe and appropriate consumer access to statins could have a significant positive public health impact. OBJECTIVES: This study compares the concordance between a participant and clinician assessment of eligibility for statin therapy using a technology-assisted approach. METHODS: A total of 500 participants, 83 with limited literacy, completed an at-home Web-based application to assess appropriateness for treatment with rosuvastatin 5 mg. The Web application is designed to assess eligibility for a moderate-intensity statin based on current guidelines and deny access to individuals with contraindications to rosuvastatin. Subsequently, participants visited a research site where clinicians, blinded to the information the participant entered, performed an independent Web application assessment. The Web application is programmed for 1 of 3 rosuvastatin treatment outcomes: "OK to use," "not right for you," or "ask a doctor." The primary endpoint was the percent of participants whose self-selected eligibility for nonprescription rosuvastatin was concordant with clinician assessment. RESULTS: For the primary endpoint, participant selection for statin therapy was concordant with clinician selection in 481 (96.2%) of 500 participants (95% confidence interval: 94.1%-97.7%), of whom 23 (4.6%) were deemed appropriate and 458 (91.6%) were deemed inappropriate for treatment. Discordance was due to incorrect self-selection ("OK to use") in 3 cases, incorrect rejection ("not right for you") in 14 cases and an incorrect "ask a doctor" outcome in 2 cases. CONCLUSIONS: The use of a technology-assisted approach to consumer self-selection for statin therapy resulted in participant self-selection that showed substantial agreement with clinician selection.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nissen SE, Hutchinson HG, Wang TY, et al. Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. J Am Coll Cardiol. 2021. PMID: 34503680. doi:10.1016/j.jacc.2021.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。